drugset / Trial / NCT02317575
A Study of LY900014 Formulations in Healthy Participants
RandomizedCrossoverDouble-blindBasic science
Summary
This study evaluated four test formulations of a glucose lowering drug (LY900014) administered by injection under the skin of the abdomen. The study was conducted in healthy people to investigate how the human body handles LY900014 and the effect of LY900014 on blood sugar levels. Side effects and tolerability were documented. The study was to be conducted in two parts (Part A and Part B) to achieve its objectives. Each part of the study was to last for about 11 to 12 weeks, including screening and follow up. Screening was required within 28 days prior to entering into either study Part A or Part B. Part B was not executed because no suitable formulation was identified.
Timeline
- Start
- 2015-01
- Primary completion
- 2015-04
- Completion
- 2015-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Insulin Lispro | Protein / enzyme biologic | 15 iu | Subcutaneous |
| Subject | Insulin Lispro | Protein / enzyme biologic | — | Subcutaneous |
Indications
No indication recorded.